- Home
- » Tags
- » Inebilizumab
Top View
- B Cells and Antibodies As Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
- Stembook 2018.Pdf
- Horizon Scanning Status Report December 2020
- Novel Emerging Treatments for NMOSD
- Uplizna™ (Inebilizumab-Cdon) (Intravenous) Document Number: IC-0549 Last Review Date: 01/01/2021 Date of Origin: 07/01/2020 Dates Reviewed: 07/2020, 10/2020, 01/2021
- Recent Biotherapies and Infections
- Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
- (INN) for Biological and Biotechnological Substances
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
- PDF of Antibody News
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- 093 Soliris, Ultomiris, and Uplizna Policy
- Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-Analysis of Randomized Control Trials
- Specialty Injectables Prior Authorization List
- Satralizumab-Mwge (Enspryng™) New Drug Update
- Soliris® [Eculizumab] and Ultomiristm [Ravulizumab]) Effective: July 13, 2021
- 5.01.564 Pharmacotherapy of Miscellaneous Autoimmune Diseases
- Inebilizumab-Cdon)
- Uplizna (Inebilizumab-Cdon) C20171-A
- The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk:Benefit Balance in Multiple Sclerosis
- Specialty Pipeline MONTHLY UPDATE
- Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated Or Associated to Immune-Mediated Inflammatory Diseases
- Eculizumab (Soliris®) and Ravulizumab (Ultomiris™)
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- A View Into Upcoming Specialty & Traditional Drugs
- CHMP Agenda of the 25-29 January 2021 Meeting
- Cytokine and CAM Antagonists and Related Agents Therapeutic
- Corporate Medical Policy Eculizumab (Soliris®) “Notification”
- MS Research Update
- Satralizumab
- Medications to Require Medical Prior Authorization, Effective Jan 1
- Targeting B Cells to Modify MS, NMOSD, and MOGAD Part 2
- 761142Orig1s000 CLINICAL REVIEW(S)
- (INN) for Biological and Biotechnological Substances
- Enspryng), Inebilizumab-Cdon (Uplizna
- Policy Title: Uplizna (Inebilizumab-Cdon) (Intravenous) Department: PHA
- Drug Information Center Highlights of FDA Activities – 6/1/2020 – 6/30/2020
- 2016 Medicines in Development for Autoimmune Diseases
- Targeting B Cells to Modify MS, NMOSD, and MOGAD Part 1
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Medical Drug Benefit Clinical Criteria Updates